stockrow
Friday 6 November 2026
Export TMCI’s income statement to Excel — free account
Treace Medical Concepts, Inc.
TMCI Healthcare Medical Devices
Treace Medical Concepts, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $212.7 million, up 1.59% from fiscal 2024.
- Revenue
- −3.91%
- EPS
- +26.9%
- Free cash flow
- +11.7%
- Total debt
- +5.11%
Quarter to September 2026, against a year earlier
3.95
0.23
−5.50%
Follow TMCI
Alert me
Treace Medical Concepts, Inc. (TMCI) P/E ratio
Treace Medical Concepts, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 24 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CLPT ClearPoint Neuro, Inc. compare | n/m |
| QSI Quantum-Si Incorporated compare | n/m |
| CV CapsoVision, Inc. compare | n/m |
| TLSI TriSalus Life Sciences, Inc. compare | n/m |
| TMCI Treace Medical Concepts, Inc. | n/m |
| PROF Profound Medical compare | n/m |
| LAB Standard BioTools Inc. compare | 1.8× |
| ELMD Electromed, Inc. compare | 19.4× |
| INFU InfuSystems Holdings, Inc. compare | 32.0× |
| Medical Devices industry median | 25.6× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)